[{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fib.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$57.2 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Neuregulin-4-based therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen T.."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Kratom Extract","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Alvogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ .."},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraGin\u00ae, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AstraGin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Scie.."},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ F.."},{"orgOrder":0,"company":"Infinant Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinant Health Announces Submission of Orphan Drug Designation Application","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INF108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infinant Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant H.."}]

Find Novel Gastroenterology Drugs in Clinical Development

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

CPhI Worldwide, Milan

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

Details : Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop fo...

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

September 14, 2023

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Infinant Health

U.S.A

26th North American ISSX

Not Confirmed

03

NuLiv Science

U.S.A

26th North American ISSX

Not Confirmed

04

Alvogen

U.S.A

26th North American ISSX

Not Confirmed

05

Tauriga Sciences

U.S.A

26th North American ISSX

Not Confirmed

06

Jaguar Health

U.S.A

26th North American ISSX

Not Confirmed

07

Hoth Therapeutics

U.S.A

26th North American ISSX

Not Confirmed